ALX Oncology Holdings Inc. has announced new data from a Phase 1b/2 clinical trial evaluating its investigational CD47-inhibitor evorpacept in combination with Jazz Pharmaceuticals' zanidatamab-hrii (ZIIHERA®) in heavily pretreated patients with metastatic HER2-positive breast cancer. The exploratory analysis indicates that CD47 expression is a predictive biomarker for response to evorpacept in combination with HER2-targeted agents. These findings are consistent with previous results from the ASPEN-06 trial in HER2-positive gastric cancer. The full data set from the biomarker analysis has been submitted for presentation at an upcoming scientific conference.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ALX Oncology Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9646127-en) on January 30, 2026, and is solely responsible for the information contained therein.